Chemogenomic profiling for blood cancers
Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)
This project will test whether detailed genetic and molecular profiling of bone marrow, blood, or tissue samples can better characterize diagnosis and relapse for people with suspected or known blood cancers.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 250 (estimated) |
| Ages | 1 Year and up |
| Sex | All |
| Sponsor | Azienda Ospedaliero-Universitaria di Parma Academic / other |
| Locations | 1 site (Parma, PR) |
| Trial ID | NCT07445984 on ClinicalTrials.gov |
What this trial studies
The project collects retrospective and prospective bone marrow, peripheral blood, lymph node or tissue samples at the University Hospital of Parma and applies genetic, molecular and multi-omics analyses. It includes a broad range of hematological malignancies defined by the WHO 2016 classification, including acute and chronic leukemias, myeloproliferative and lymphoproliferative disorders, and myelodysplastic syndromes. The work seeks to link molecular and chemogenomic signatures with diagnostic categories, relapsed/refractory disease and blastic transformation. Findings are intended to inform more precise diagnosis and to generate hypotheses about potential therapeutic targets.
Who should consider this trial
Good fit: Patients of any age over 1 year who are referred to the University Hospital of Parma with suspected or confirmed hematological malignancies, including new diagnoses, relapsed/refractory cases, or blastic transformation, are the intended participants.
Not a fit: Patients who do not have available stored samples at Parma, who cannot undergo diagnostic sampling, or whose condition is non-hematologic are unlikely to benefit from this project.
Why it matters
Potential benefit: If successful, the profiling could help doctors identify disease subtypes and potential targeted treatments more quickly and accurately.
How similar studies have performed: Related genomic and molecular profiling efforts in blood cancers have identified actionable mutations and informed therapy in some cases, but broader chemogenomic panels remain under validation for routine clinical use.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient aged \>1 year old, referred for evaluation to the University Hospital of Parma; * Retrospective study: previously patients with hematological malignancies; * Prospective study: 1) patients with clinical suspect of hematological malignancies which requires a diagnostic assessment using peripheral blood drawn, bone marrow aspirate/biopsy, lymph nodes biopsies or biopsies of tissues with metastatic involvement including liquor from rachicentesis, tissue aspirate etc. 2) patients with clinical suspect of relapsed/refractory onco-hematological disorder, which requires a diagnostic assessment using bone marrow aspirate/biopsy or biopsies of tissues with metastatic involvement including lymph nodes, liquor from rachicentesis, tissue aspirate etc. 3) patients that progress in blastic transformation from a chronic condition or suspect of relapsed/refractory hematological disease, which requires a diagnostic assessment using peripheral blood drawn, bone marrow aspirate/biopsy, lymph nodes biopsies or biopsies of tissues with metastatic involvement including liquor from rachicentesis, tissue aspirate etc; * Written informed consent. Retrospective study: informed consent will be signed during the first follow-up visit. Exclusion Criteria: * Age \<1 year old * Patients who are unable to provide informed consent prior to any procedure for any reason.
Where this trial is running
Parma, PR
- University of Parma — Parma, Pr, Italy (Recruiting)
Study contacts
- Study coordinator: Giovanni Roti, Associate Professor
- Email: giovanni.roti@unipr.it
- Phone: +39 0521 702200
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.